Four-year outcomes with third-generation centrifugal left ventricular assist devices in an era of restricted transplantation.
Bottom Line: Older age and more acute INTERMACS groups were significantly related to reduced survival within the first 90 days (P = 0.030 and 0.010, respectively).Poor preoperative right ventricular (RV) function had a negative effect on survival after 1 year (P = 0.009), though not earlier.Only 14 of 102 patients were transplanted at a median of 334 ± 347 days, and only 3 were transplanted within the first 6 months.
Affiliation: Departments of Cardiothoracic Surgery and Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.Show MeSH
Related in: MedlinePlus
Mentions: The timeline of the changes in the anticoagulation regime relative to the incidence of new VAD thromboses for HeartWare VADs only (divided into 6 monthly intervals noted as ‘a’ and ‘b’) is shown in Fig. 6. During the study period, there has been a change in the design of the HeartWare VAD inflow cannula in the form of a sintered area on the outer side facing the ventricle cavity to encourage epithelialisation that would reduce thrombus formation. The first of these sintered devices was implanted in September 2011 in this series. This had no significant antithrombotic effect in our cohort (P = NS, data not shown).Figure 6:
Affiliation: Departments of Cardiothoracic Surgery and Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.